Skip to main content
TipRanks
Go Ultimate75% OFF

JASON GARDNER Insider Profile

4 Followers

JASON GARDNER, President & CEO, Director at Dianthus Therapeutics, holds 944.95K shares in Dianthus Therapeutics (Ticker: DNTH).

JASON GARDNER's Trading History

DNTH
Dianthus Therapeutics
Dec 02, 2022President & CEO, DirectorUninformative Buy2.82K$86.76M
DNTH
Insider Shares: 944.95K (1.56%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Dec 02, 2022Uninformative Buy$2.82K3,000$0.94―
Jun 06, 2022Uninformative Buy$2.97K3,000$0.99―
Sep 20, 2021Informative Sell$96.51K14,340$6.73+77.80%
Sep 16, 2021Uninformative Buy$0.0050,000$0.00―
Jan 10, 2020Uninformative Sell$170.80K11,200$15.25―

You May Also Like

JASON GARDNER insider profile FAQ

What is the percentage of profitable transactions made by JASON GARDNER?
The percentage of profitable transactions made by JASON GARDNER is 100%.
What is the average return per transaction made by JASON GARDNER?
The average return per transaction made by JASON GARDNER is 41.30%.
What stocks does JASON GARDNER hold?
JASON GARDNER holds: DNTH stocks.
What was JASON GARDNER’s latest transaction?
JASON GARDNER’s latest transaction was an Uninformative Buy of $2.82K.
What was JASON GARDNER's most profitable transaction?
JASON GARDNER’s most profitable transaction was an Informative Sell of DNTH stock on September 20, 2021. The return on the trade was 77.80%.
What is JASON GARDNER's role in Dianthus Therapeutics?
JASON GARDNER's role in Dianthus Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.